Global Leading Market Research Publisher QYResearch announces the release of its latest report “AKR7A2 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global AKR7A2 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for AKR7A2 Antibody was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
For toxicologists, chemoprevention researchers, and drug metabolism scientists, four persistent experimental pain points dominate AKR7A2-related workflows: validating AKR7A2 (Aldo-Keto Reductase Family 7 Member A2, also known as AFAR, AFB1 aldehyde reductase, or AKR7A2) expression in liver and other detoxification tissues, distinguishing monoclonal vs. polyclonal antibody performance across applications (western blot, IHC, IF, ELISA), detecting AKR7A2 without cross-reactivity to other aldo-keto reductase family members (AKR7A3, AKR1C1-4, AKR1B1), and maintaining lot-to-lot consistency for longitudinal chemoprevention studies. This AKR7A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 101-129 amino acids from the N-terminal region of human. Growing patient base, launch of AKR7A2 antibody-based therapeutics, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in AKR7A2 antibody market revenue. This report delivers a data-driven roadmap for toxicology researchers, cancer prevention scientists, and drug metabolism investigators.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984529/akr7a2-antibody
1. Market Drivers and Research Demand (2025–2026 Update)
AKR7A2 is a member of the aldo-keto reductase superfamily, localized predominantly in liver and kidney, responsible for detoxifying reactive aldehydes including aflatoxin B1 dialdehyde (AFB1-derived), succinic semialdehyde, and other lipid peroxidation products. It reduces aldehyde groups to alcohols, facilitating conjugation and excretion. AKR7A2 is induced by Nrf2-activating chemopreventive agents (sulforaphane, oltipraz, curcumin). Demand drivers include:
- Aflatoxin detoxification research: AKR7A2 is the primary enzyme reducing aflatoxin B1 dialdehyde, a highly reactive genotoxic metabolite; antibody used in HCC risk studies (hepatocellular carcinoma, high incidence in Sub-Saharan Africa, Southeast Asia)
- Chemoprevention mechanism studies: AKR7A2 induction by Nrf2 activators correlates with protection against AFB1-induced liver cancer; antibody used to validate enzyme expression
- Drug metabolism and toxicology: AKR7A2 involved in metabolism of certain drugs and environmental toxins; antibody used for tissue distribution studies
- Neuroprotection: AKR7A2 reduces succinic semialdehyde (GABA metabolism); potential role in neuroprotection against aldehyde stress
Based on supplier catalog data (Abcam, Thermo Fisher, Proteintech, Novus), AKR7A2 antibody unit sales grew 6–8% YoY (2024–2025), driven by expanded use in chemoprevention studies and increasing aflatoxin research in China and Africa (>30 AKR7A2-related publications in 2025).
2. Monoclonal vs. Polyclonal AKR7A2 Antibodies
| Parameter | Monoclonal AKR7A2 Antibody | Polyclonal AKR7A2 Antibody |
|---|---|---|
| Specificity | Very high (single epitope) | High (multiple epitopes) |
| Batch consistency | Excellent (identical) | Variable |
| IHC/IF performance | Excellent (low background) | Good (affinity-purified) |
| WB performance | Clean single band (~40 kDa) | Single band if affinity-purified |
| IP performance | Variable | Good (multiple epitopes) |
| Cross-reactivity to AKR7A3 | Low (if epitope chosen in divergent region) | Moderate (high sequence identity) |
| Market share | ~48% | ~52% |
Critical note – AKR7A2 vs. AKR7A3 cross-reactivity: AKR7A2 and AKR7A3 share ~85% amino acid identity. Polyclonal antibodies raised against full-length or C-terminal regions may cross-react. The peptide antigen used (aa 101-129, N-terminal region) is less conserved, improving specificity. Researchers should check datasheet for AKR7A3 cross-reactivity data.
3. Application Performance Requirements
| Application | Share | Key Requirements | Preferred Type | Dilution |
|---|---|---|---|---|
| Western Blot (WB) | ~35% | Single band ~40 kDa; positive control: human liver lysate, HepG2 cells | Both | 1:500–1:2,000 |
| Immunohistochemistry (IHC) | ~25% | FFPE liver tissue; cytoplasmic staining (peroxisomal/cytoplasmic localization) | Monoclonal or affinity-purified | 1:50–1:500 |
| Immunofluorescence (IF) | ~20% | Cytoplasmic staining; colocalization with peroxisomal markers (PMP70, catalase) | Monoclonal | 1:50–1:250 |
| ELISA | ~10% | Lysate or tissue homogenate quantitation | Monoclonal | 1:500–1:5,000 |
| Immunoprecipitation (IP) | ~5% | Native AKR7A2 pull-down | Polyclonal | 2–10 μg/IP |
| Others | ~5% | Flow cytometry, tissue arrays | Monoclonal | 1:50–1:200 |
Typical case – Aflatoxin chemoprevention study (China, 2025):
A Shanghai research center studying sulforaphane-mediated chemoprevention of AFB1-induced liver cancer used rabbit polyclonal AKR7A2 antibody (1:1,000 WB, 1:200 IHC). In HepG2 cells treated with sulforaphane (10 μM, 24h), AKR7A2 protein increased 3.2-fold (p<0.001). In rat liver (n=20, sulforaphane 10 mg/kg/day x 7 days), IHC showed AKR7A2 induction in centrilobular hepatocytes (zone 3). The antibody recognized both human and rat AKR7A2 (94% identity). Pre-absorption with immunizing peptide abolished signal, confirming specificity.
Typical case – Liver cancer risk biomarker (US/Gambia collaborative, 2025):
A collaborative study between US NIH and Gambian researchers analyzed AKR7A2 expression in 120 human liver biopsies (control, chronic hepatitis B, cirrhosis, HCC). Using monoclonal mouse anti-AKR7A2 antibody (clone 4G11), IHC (1:100) showed progressive AKR7A2 loss with disease progression:
- Control liver: strong cytoplasmic staining (H-score 210±25)
- Chronic HBV: moderate reduction (165±30, p<0.01)
- Cirrhosis: weak staining (95±20, p<0.001)
- HCC: absent/weak in tumor cells (45±15, p<0.001)
AKR7A2 loss may represent reduced detoxification capacity, contributing to HCC risk. The monoclonal antibody enabled consistent scoring across 2 centers.
4. Technical Bottlenecks and Quality Considerations
AKR7A2 as Nrf2 target – validation of induction: AKR7A2 is transcriptionally regulated by Nrf2. For chemoprevention studies, validate with Nrf2 activators (sulforaphane, CDDO-Im) and Nrf2 siRNA/knockout controls to confirm antibody detects induced AKR7A2 specifically.
Cross-reactivity with AKR7A3:
| Parameter | AKR7A2 | AKR7A3 |
|---|---|---|
| MW | ~40 kDa | ~39 kDa |
| Identity | 100% | ~85% |
| Tissue distribution | Liver, kidney | Liver (lower), testis |
| Function | AFB1 aldehyde reductase | AFB1 aldehyde reductase (minor) |
Most commercial polyclonal antibodies cross-react partially with AKR7A3. For AKR7A2-specific studies, use monoclonal antibody with demonstrated lack of AKR7A3 reactivity (check datasheet) or knockdown/KO validation.
Species cross-reactivity:
| Species | Identity to Human | Antibody Recognition | Notes |
|---|---|---|---|
| Human | 100% | Yes (validated) | Positive control: liver lysate |
| Rat | 94% | Yes (most commercial) | Positive control: rat liver |
| Mouse | 92% | Yes (most commercial) | Positive control: mouse liver |
| Rabbit | 88% | Variable | Check datasheet |
Exclusive forward view – AKR7A2 in precision chemoprevention:
Genetic polymorphisms in AKR7A2 (e.g., rs1132453, rs2073268) affect enzyme activity and cancer risk. AKR7A2 antibody used in:
- Population studies: IHC to correlate genotype with protein expression (n=500+, ongoing China/UK)
- Functional assays: Antibody-based capture of AKR7A2 from human liver samples for enzyme activity measurements
- Pharmacodynamic assays: AKR7A2 protein levels as biomarker of Nrf2 activator engagement (Phase II chemoprevention trials)
5. Regional Market Dynamics
| Region | Share | Key Drivers |
|---|---|---|
| North America | ~40% | NIH chemoprevention funding (NCI); aflatoxin research (NIEHS); drug metabolism studies |
| Asia-Pacific | ~35% | China (largest market: aflatoxin research, liver cancer prevention, >30 AKR7A2 publications 2025); Southeast Asia (high AFB1 exposure); Japan, South Korea |
| Europe | ~18% | Toxinology research; chemoprevention consortia; liver research |
| Africa | ~5% | Emerging aflatoxin research (Gambia, Kenya, Nigeria) |
| Rest of World | ~2% | South America, Middle East |
Exclusive note – Africa growth potential: Aflatoxin B1 is a major cause of hepatocellular carcinoma in Sub-Saharan Africa. International agencies (IARC, WHO, Gates Foundation) fund aflatoxin biomarker studies using AKR7A2 IHC and WB. Growth is modest due to limited research infrastructure but shows potential for 2027-2030.
6. Competitive Landscape
Leading players covered in this report (full list): ProSci, Thermo Fisher Scientific, Aviva Systems Biology, RayBiotech, LifeSpan BioSciences, Abcam, HUABIO, Leading Biology, Novus Biologicals, ABclonal Technology, OriGene Technologies, GeneTex, Affinity Biosciences, Proteintech Group, BosterBio, CUSABIO Technology, Bioss, Abbexa, Biobyt, Jingjie PTM BioLab.
Tier 1 suppliers: Abcam, Thermo Fisher, Proteintech, Novus — multiple clones (monoclonal + polyclonal), KO validation for select products, extensive application data.
Chemoprevention/toxicology specialists: Abcam (ab189850, rabbit polyclonal, raised against N-terminal peptide, aa 101-129); Thermo Fisher (PA5-116307, rabbit polyclonal, IHC-validated); Proteintech (16512-1-AP, rabbit polyclonal, highly cited for WB).
Price/performance: BosterBio, Bioss, GeneTex, Affinity Biosciences — adequate for routine WB, lower cost.
7. Market Segmentation Summary
Segment by Type: Monoclonal, Polyclonal
Segment by Application: Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
